Media stories about Akari Therapeutics PLC (NASDAQ:AKTX) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Akari Therapeutics PLC earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.5713514447992 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of brokerages have recently issued reports on AKTX. William Blair downgraded shares of Akari Therapeutics PLC from an “outperform” rating to a “market perform” rating in a research report on Friday, May 12th. Zacks Investment Research downgraded shares of Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Chardan Capital upgraded shares of Akari Therapeutics PLC from a “sell” rating to a “neutral” rating and dropped their price target for the stock from $6.50 to $6.00 in a research report on Wednesday, May 31st. Finally, Canaccord Genuity restated a “buy” rating and issued a $15.00 price target (down previously from $33.00) on shares of Akari Therapeutics PLC in a research report on Monday, June 26th.

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) traded up 1.3859% on Friday, hitting $3.5992. 14,019 shares of the stock were exchanged. The company has a 50 day moving average of $4.13 and a 200 day moving average of $7.39. Akari Therapeutics PLC has a 52-week low of $3.18 and a 52-week high of $22.20. The company’s market cap is $42.38 million.

COPYRIGHT VIOLATION WARNING: “Akari Therapeutics PLC (AKTX) Earning Somewhat Favorable Press Coverage, Accern Reports” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at

About Akari Therapeutics PLC

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Insider Buying and Selling by Quarter for Akari Therapeutics PLC (NASDAQ:AKTX)

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.